Develop vector-ecology intervention technologies to reduce disease-transmission risks
Establish a cross-host virus detection and risk-interruption platform
Establish a knowledge base for the pathogenesis and immune regulation of emerging pathogens
Develop modular vaccine and antiviral technology platforms
Apply AI and interdisciplinary models to predict transmission hotspots and advance policy translation
This project establishes a vector mosquito manipulation platform incorporating cutting-edge technologies such as gene drive and reproductive suppression, and integrates geographic and climate data to build dynamic predictive models that accurately simulate vector dynamics and virus transmission hotspots. Simultaneously, ecological intervention and monitoring demonstrations are conducted in high-risk areas for dengue, chikungunya, and Japanese encephalitis to thoroughly validate the epidemic prevention efficacy of these innovative technologies, thereby accelerating their future large-scale deployment and application.
This project collects samples from high-risk animals, including avian species, bats, rodents, and primates, to monitor potential viral threats in real time. It applies viral cultivation, next-generation sequencing, and adaptive simulation technologies to thoroughly assess the potential risk of viruses crossing species barriers to infect humans. Concurrently, it develops molecular or immunological interruption mechanisms to sever potential transmission chains, comprehensively reinforcing cross-host epidemic prevention barriers.
This project focuses on key viruses with high epidemic potential and pandemic threats (such as H5/H7 subtype avian influenza, SARS-like coronaviruses, and Nipah virus), conducting in-depth epidemiological and etiological surveillance. It comprehensively decodes core viral pathogenic factors and immune evasion mechanisms, precisely revealing host-pathogen interactions to lay a solid scientific foundation for subsequent candidate vaccine development and innovative therapeutics. Concurrently, it establishes a rapid and highly secure experimental technology platform for high-risk pathogens, ensuring that pathogen research and risk assessment can be swiftly initiated under rigorous biosafety containment during emerging infectious disease threats.
By integrating diversified R&D platforms—including mRNA vaccines, viral vectors, recombinant protein vaccines, and small-molecule antiviral drugs—the project builds a flexible and resilient technology matrix. It constructs a rapid "Pathogen-to-Product" response pipeline, drastically shortening the response time from initial genomic sequencing of an emerging pathogen to the production of candidate vaccines and therapeutics. Furthermore, it establishes close linkages with national vaccine task forces and public health systems to accelerate the clinical translation and industrialization of research outcomes, directly supporting national public health defense strategies.
The project cross-disciplinarily integrates multi-source big data—encompassing environmental climate, veterinary epidemiology, human surveillance, and viral genomics—to build a comprehensive intelligence database. By deploying artificial intelligence and machine learning models, it accurately predicts viral evolutionary trends, key genetic mutations, cross-species transmission potential, and geographical dissemination risks. Finally, it translates forward-looking scientific achievements into concrete public health policy recommendations and functional epidemic prevention products, while promoting international collaboration to expand global health security impact.
Our laboratory primarily focuses on emerging viruses, including influenza, dengue virus, enterovirus, and Coronavirus. Our core research encompasses the development of detection technologies for novel and mutant strains, the intricate mechanisms of virus-host interactions, and the advancement of antiviral drug discovery.
By decoding the mechanisms of cross-species transmission, molecular pathogenesis, and critical molecular targets, our team is dedicated to the rapid and precise identification of pathogens during outbreaks. We aim to clarify biological characteristics and origins to develop effective prevention strategies and interrupt infection chains.
Looking forward, we are addressing emerging infectious diseases in the context of global warming, deepening our study of cross-species transmission, and building a robust international collaboration network to contribute to global public health security.
Consolidated Research Findings and Publications on Enteroviruses from the SRS Lab
Consolidated Research Findings and Publications on influenza virus from the SRS Lab
Our laboratory is dedicated to deconstructing the life cycles of RNA viruses, with a primary focus on Enterovirus, Influenza, and Coronaviruses. We investigate how viral non-translated regions (UTRs) regulate translation and explore the mechanisms by which viral proteins disrupt host cellular processes, such as apoptosis regulation. By unraveling these fundamental molecular interactions, we identify the core drivers of viral pathogenesis, providing critical scientific evidence for the clinical prediction of severe disease.
In response to the continuous evolution of emerging viruses, our laboratory integrates genomic surveillance, molecular evolution, and statistical analysis to track viral mutation trends and geographic transmission pathways. Our work encompasses cross-species transmission of influenza and the monitoring of SARS-CoV-2 variants. These big data-driven insights provide critical early-warning information for public health policies and are essential for evaluating the efficacy of current diagnostics and clinical treatments.
Recent Publications
Utilizing clinical samples from natural infections and vaccinations, our team evaluates the persistence and cross-protective efficacy of host neutralizing antibodies. We place a particular emphasis on immune system dynamics within specific populations, such as medical staffs and hemodialysis patients, while exploring immune cross-reactivity between different viruses. Our findings provide critical scientific foundations for the precision design of next-generation vaccines and the optimization of clinical immunization strategies.
Our team is committed to advancing translational research for emerging infectious diseases. Leveraging our insights into viral vulnerabilities, we focus on two core areas: on the therapeutic front, we develop potent broad-spectrum antiviral peptides, novel antibody-based drugs, and natural extracts; on the diagnostic front, we integrate interdisciplinary engineering to build high-sensitivity biosensing platforms. Through this dual-track R&D approach, we aim to achieve precision screening and early therapeutic intervention against emerging viral threats.